New targeted therapy to stop bone loss in prostate cancer patients
August 21st, 2009 Posted in hormone therapyAccording to a study supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF), twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM).